Key result
Anti-platelet factor 4/heparin antibodies independently predicted 30-day death or myocardial infarction in patients with acute coronary syndrome (OR 4.0; 95% CI 1.4-11.3; P=0.0093).
Why the study?
Does the presence of anti-platelet factor 4/heparin antibodies predict recurrent ischemic events in patients with acute coronary syndrome?
Population
218 patients with acute coronary syndrome from the placebo/unfractionated heparin arm of the GUSTO IV-ACS…
Comparison
Presence of anti-platelet factor 4/heparin… vs Absence of anti-platelet factor 4/heparin…
Design
Case-control, analyses were done by blinded investigators
Follow-up
30 days
Authors
Loading...
May aid ACS risk stratification; hypothesis-generating and requires prospective validation before guiding therapy.
Case-Control (n=218)
Blinded investigators
Does the presence of anti-platelet factor 4/heparin antibodies predict recurrent ischemic events in patients with acute coronary syndrome?
Odds Ratio: 4 (95% CI 1.4–11.3)
Absolute Event Rate: 30.4% vs 11.3%
p-value: p=0.0093
Anti-PF4/heparin antibodies independently predict 30-day myocardial infarction in ACS patients, potentially explaining adverse events linked to thrombocytopenia and informing anticoagulant selection.
Williams et al. (2003) conducted a case-control in Acute coronary syndrome (n=218). Anti-platelet factor 4/heparin antibodies vs. Negative for anti-PF4/heparin antibodies was evaluated on 30-day death or myocardial infarction (OR 4.0, 95% CI 1.4 to 11.3, p=0.0093). Anti-platelet factor 4/heparin antibodies independently predicted 30-day death or myocardial infarction in patients with acute coronary syndrome (OR 4.0; 95% CI 1.4-11.3; P=0.0093).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: